Accessibility Menu
NeoGenomics Stock Quote

NeoGenomics (NASDAQ: NEO)

$10.27
(-0.7%)
-0.07
Price as of October 23, 2025, 9:30 a.m. ET

KEY DATA POINTS

Current Price
$10.27
Daily Change
(-0.7%) $0.07
Day's Range
$10.26 - $10.35
Previous Close
$10.34
Open
$10.35
Beta
1.58
Volume
15,962
Average Volume
3,439,300
Market Cap
1.3B
Market Cap / Employee
$10.34M
52wk Range
$4.72 - $19.12
Revenue
-
Gross Margin
0.41%
Dividend Yield
N/A
EPS
-$0.82
CAPs Rating
-
Industry
Healthcare Providers and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

NeoGenomics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
NEO-21.79%-74.99%-24.21%+301%
S&P+14.5%+93.32%+14.09%+482%

NeoGenomics Company Info

NeoGenomics is a provider of genetic testing, specializing in cancer diagnostics.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$181.33M10.2%
Gross Profit$73.95M7.1%
Gross Margin40.78%-1.2%
Market Cap$940.76M-46.9%
Market Cap / Employee$0.43M0.0%
Employees2.2K4.8%
Net Income-$45.09M-141.9%
EBITDA-$2.02M11.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$154.72M-56.4%
Accounts Receivable$153.13M4.5%
Inventory34.247.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$407.71M1.2%
Short Term Debt$4.05M-98.0%

Ratios

Q2 2025YOY Change
Return On Assets-6.85%-2.1%
Return On Invested Capital-4.15%-1.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$14.01M1620.8%
Operating Free Cash Flow$20.33M46.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.082.321.351.06-44.81%
Price to Sales2.913.171.801.36-51.37%
Price to Tangible Book Value50.5056.4330.4827.45-44.28%
Enterprise Value to EBITDA-949.17800.45-204.60-585.25-32.03%
Return on Equity-8.4%-8.5%-8.6%-11.8%40.10%
Total Debt$606.27M$605.33M$604.78M$411.76M-32.11%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.